Peter S. Kim Buys 1,512 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 1,512 shares of the stock in a transaction dated Thursday, March 28th. The shares were bought at an average cost of $13.75 per share, with a total value of $20,790.00. Following the completion of the transaction, the director now owns 60,336 shares of the company's stock, valued at approximately $829,620. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Entrada Therapeutics Trading Down 2.9 %

TRDA stock traded down $0.41 during trading on Monday, hitting $13.76. 70,847 shares of the company's stock were exchanged, compared to its average volume of 77,841. The business has a 50-day moving average price of $13.78 and a two-hundred day moving average price of $14.52. The stock has a market capitalization of $462.34 million, a price-to-earnings ratio of -52.92 and a beta of -0.50. Entrada Therapeutics, Inc. has a 52-week low of $10.62 and a 52-week high of $18.44.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its stake in Entrada Therapeutics by 1.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,014,377 shares of the company's stock valued at $40,754,000 after buying an additional 42,327 shares during the last quarter. BlackRock Inc. lifted its stake in Entrada Therapeutics by 563.2% in the second quarter. BlackRock Inc. now owns 1,405,806 shares of the company's stock valued at $21,284,000 after buying an additional 1,193,821 shares during the last quarter. Vanguard Group Inc. lifted its stake in Entrada Therapeutics by 4.4% in the fourth quarter. Vanguard Group Inc. now owns 1,065,166 shares of the company's stock valued at $16,073,000 after buying an additional 44,849 shares during the last quarter. Wellington Management Group LLP lifted its stake in Entrada Therapeutics by 2.6% in the third quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company's stock valued at $16,521,000 after buying an additional 26,144 shares during the last quarter. Finally, FMR LLC lifted its stake in Entrada Therapeutics by 7.8% in the second quarter. FMR LLC now owns 944,908 shares of the company's stock valued at $11,509,000 after buying an additional 68,114 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Monday, March 18th. Oppenheimer assumed coverage on Entrada Therapeutics in a research report on Friday, January 5th. They set an "outperform" rating and a $22.00 price objective for the company.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.